Tommy Thompson Net Worth

The estimated Net Worth of Tommy G Thompson is at least $7.38 Million dollars as of 26 June 2024. Tommy Thompson owns over 7,500 units of United Therapeutics Corp stock worth over $5,532,116 and over the last 20 years he sold UTHR stock worth over $1,425,546. In addition, he makes $426,945 as Independent Director at United Therapeutics Corp.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Tommy Thompson UTHR stock SEC Form 4 insiders trading

Tommy has made over 101 trades of the United Therapeutics Corp stock since 2006, according to the Form 4 filled with the SEC. Most recently he exercised 7,500 units of UTHR stock worth $1,315,725 on 26 June 2024.

The largest trade he's ever made was exercising 145,296 units of United Therapeutics Corp stock on 10 August 2021 worth over $50,300,022. On average, Tommy trades about 2,784 units every 27 days since 2005. As of 26 June 2024 he still owns at least 15,980 units of United Therapeutics Corp stock.

You can see the complete history of Tommy Thompson stock trades at the bottom of the page.

Tommy Thompson biography

Gov. Hon. Tommy G. Thompson J.D. serves as Independent Director of the Company. Before entering the private sector in 2005, Governor Thompson enjoyed a long and distinguished career in public service. As Secretary of the U.S. Department of Health and Human Services from 2001 to 2005, he was a leading advocate for the health and welfare of all Americans. He also served four terms as Governor of Wisconsin from 1987 to 2001. Governor Thompson served as a partner at the law firm of Akin Gump Strauss Hauer & Feld LLP (Akin Gump) in Washington, D.C. from 2005 until January 2012. Governor Thompson has served as Chairman and Chief Executive Officer of Thompson Holdings, a consulting firm, since 2012. In 2017, Governor Thompson became an Adjunct Senior Advisor to Akin Gump. From 2005 to 2009, he also served as the Independent Chairman of the Deloitte Center for Health Solutions, which researches and develops solutions to some of our nation’s most pressing health care and public health related challenges. He is currently a member of the boards of directors of the following public companies: Centene Corporation, Physicians Realty Trust, and TherapeuticsMD, Inc. He previously served on the boards of various other public companies, including Cancer Genetics Inc., CareView Communications, Inc., CNS Response, Inc., C.R. Bard, Inc., Cytori Therapeutics, Inc., SpectraScience, Tyme Technologies, Inc., and X Shares Advisors, and as the chairman of the board of directors of AGA Medical Holdings, Inc. from 2005 to 2010. Our Board has determined that Governor Thompson meets the financial sophistication requirements of Nasdaq’s listing standards.

What is the salary of Tommy Thompson?

As the Independent Director of United Therapeutics Corp, the total compensation of Tommy Thompson at United Therapeutics Corp is $426,945. There are 14 executives at United Therapeutics Corp getting paid more, with Martine Rothblatt having the highest compensation of $15,627,500.

How old is Tommy Thompson?

Tommy Thompson is 78, he's been the Independent Director of United Therapeutics Corp since 2010. There are 1 older and 18 younger executives at United Therapeutics Corp. The oldest executive at United Therapeutics Corp is Louis Sullivan, 86, who is the Independent Director.

What's Tommy Thompson's mailing address?

Tommy's mailing address filed with the SEC is C/O UNITED THERAPEUTICS CORPORATION, 1000 SPRING STREET, SILVER SPRING, MD, 20910.

Insiders trading at United Therapeutics Corp

Over the last 20 years, insiders at United Therapeutics Corp have traded over $68,910,395 worth of United Therapeutics Corp stock and bought 229,703 units worth $13,655,671 . The most active insiders traders include Martine A Rothblatt, David Zaccardelli, and Roger Jeffs. On average, United Therapeutics Corp executives and independent directors trade stock every 3 days with the average trade being worth of $2,310,818. The most recent stock trade was executed by James Edgemond on 9 September 2024, trading 8,332 units of UTHR stock currently worth $991,341.

What does United Therapeutics Corp do?

united therapeutics corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. we currently have five approved products on the market, and a long-term mission of providing an unlimited supply of transplantable organs for those who need them! our employees can be found collaborating across the united states, europe and asia. as a group, we are relentless in our pursuit of “medicines for life” and continue to research and develop treatments for cardiovascular and pulmonary diseases, pediatric cancers, and other orphan diseases. #weareunitherians

Complete history of Tommy Thompson stock trades at Cancer Genetics, United Therapeutics Corp, Centene, Healthpeak Properties, TherapeuticsMD, Tyme Technologies Inc, and TherapeuticsMD Inc

United Therapeutics Corp executives and stock owners

United Therapeutics Corp executives and other stock owners filed with the SEC include:

• Martine Rothblatt,
  Chairman of the Board, Chief Executive Officer
• Michael Benkowitz,
  President, Chief Operating Officer
• Paul Mahon,
  Executive Vice President, General Counsel, Corporate Secretary
• James Edgemond,
  Chief Financial Officer, Treasurer
• Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D.,
  Founder, Chairman & CEO
• Dr. Martine A. Rothblatt,
  Founder, Chairman & CEO
• Michael I. Benkowitz,
  Pres & COO
• Paul A. Mahon,
  Exec. VP, Gen. Counsel & Corp. Sec.
• Paul A. Mahon J.D.,
  Exec. VP, Gen. Counsel & Corp. Sec.
• James C. Edgemond,
  CFO & Treasurer
• Christopher Patusky,
  Lead Independent Vice Chairman of the Board
• Christopher Causey,
  Independent Director
• Richard Giltner,
  Independent Director
• Louis Sullivan,
  Independent Director
• Tommy Thompson,
  Independent Director
• Nilda Mesa,
  Independent Director
• Judy Olian,
  Independent Director
• Katherine Klein,
  Independent Director
• Raymond Kurzweil,
  Independent Director
• Raymond Dwek,
  Independent Director
• Linda Maxwell,
  Director
• Dewey Steadman C.F.A.,
  Head of Investor Relations
• Leigh Peterson,
  VP of Product Devel.
• Gil Golden,
  Sr. VP & Chief Medical Officer
• Patrick Poisson,
  Exec. VP of Technical Operations
• Kevin T. Gray,
  Sr. VP of Strategic Operations & Logistics
• Holly Hobson,
  Associate VP of HR
• Dewey Steadman C.F.A., CFA,
  Head of Investor Relations
• Jan Malcolm,
  
• Ray Kurzweil,
  
• Roger Jeffs,
  President & COO
• Fred T Hadeed,
  EVP & CFO
• David Zaccardelli,
  EVP & Chief Operating Officer
• John Maxim Ferrari,
  CFO & Treasurer
• R Paul Gray,
  Director
• Lilly & Co Eli,
  Director, Chairman and CEO